Pfizer Inc. NYSE PFE today announced the United States U.S. Food and Drug Administration FDA has approved ABRILADA adalimumabafzb as a biosimilar to Humira adalimumab1 for the treatment of certain patients with rheumatoid arthritis juvenile idiopathic art...
↧